Galectin Therapeutics Inc. (NASDAQ:GALT) Shares Bought by Barclays PLC

Barclays PLC lifted its position in shares of Galectin Therapeutics Inc. (NASDAQ:GALT) by 309.0% in the third quarter, according to the company in its most recent 13F filing with the Securities & Exchange Commission. The fund owned 28,587 shares of the company’s stock after buying an additional 21,598 shares during the period. Barclays PLC’s holdings in Galectin Therapeutics were worth $79,000 as of its most recent SEC filing.

Other large investors have also made changes to their positions in the company. Commonwealth Equity Services LLC increased its holdings in Galectin Therapeutics by 317.6% in the 2nd quarter. Commonwealth Equity Services LLC now owns 483,351 shares of the company’s stock valued at $1,092,000 after purchasing an additional 367,610 shares in the last quarter. Sanctuary Advisors LLC purchased a new stake in shares of Galectin Therapeutics in the second quarter worth about $227,000. Bank of New York Mellon Corp acquired a new stake in shares of Galectin Therapeutics in the second quarter valued at about $146,000. Kovitz Investment Group Partners LLC purchased a new stake in shares of Galectin Therapeutics during the 3rd quarter valued at about $117,000. Finally, Squarepoint Ops LLC lifted its position in Galectin Therapeutics by 75.4% during the 2nd quarter. Squarepoint Ops LLC now owns 84,074 shares of the company’s stock worth $190,000 after acquiring an additional 36,139 shares in the last quarter. 11.68% of the stock is owned by hedge funds and other institutional investors.

Galectin Therapeutics Stock Performance

Shares of Galectin Therapeutics stock opened at $1.13 on Friday. The firm has a market cap of $70.92 million, a PE ratio of -1.55 and a beta of 0.83. Galectin Therapeutics Inc. has a 1 year low of $0.73 and a 1 year high of $4.27. The firm’s 50-day simple moving average is $2.10 and its 200-day simple moving average is $2.35.

Analysts Set New Price Targets

GALT has been the subject of several recent analyst reports. HC Wainwright restated a “neutral” rating on shares of Galectin Therapeutics in a research note on Friday, December 27th. StockNews.com downgraded Galectin Therapeutics from a “hold” rating to a “sell” rating in a report on Monday, December 30th.

Insider Buying and Selling

In related news, CFO Jack W. Callicutt sold 40,000 shares of Galectin Therapeutics stock in a transaction dated Monday, December 23rd. The shares were sold at an average price of $0.89, for a total value of $35,600.00. Following the sale, the chief financial officer now directly owns 7,614 shares in the company, valued at $6,776.46. This trade represents a 84.01 % decrease in their position. The sale was disclosed in a document filed with the SEC, which is available through this hyperlink. Also, CEO Joel Lewis sold 56,000 shares of the business’s stock in a transaction dated Monday, December 23rd. The shares were sold at an average price of $0.89, for a total transaction of $49,840.00. Following the transaction, the chief executive officer now directly owns 897,012 shares of the company’s stock, valued at $798,340.68. The trade was a 5.88 % decrease in their ownership of the stock. The disclosure for this sale can be found here. Over the last ninety days, insiders have bought 22,000 shares of company stock worth $30,540 and have sold 109,654 shares worth $97,456. 50.10% of the stock is currently owned by company insiders.

About Galectin Therapeutics

Galectin Therapeutics Inc, a clinical stage biopharmaceutical company, engages in the research and development of therapies for fibrotic, cancer, and other diseases. Its lead product candidate is belapectin (GR-MD-02) galectin-3 inhibitor, that is in Phase 2b/3 clinical trial, to prevent esophageal varices in patient with non-alcoholic steatohepatitis (NASH) cirrhosis; and Phase 2 clinical trial for the treatment of liver fibrosis, as well as severe skin disease, and melanoma and head and neck squamous cell carcinoma.